Who are Insulin Glargine - Insulin Aspart's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tresiba, Levemir, Apidra, Novolog, Lantus, Humalog.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/insulin-glargine-insulin-aspart.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Insulin Glargine - Insulin Aspart — Competitive Intelligence Brief

Insulin Glargine - Insulin Aspart (Insulin Glargine - Insulin Aspart) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin combination therapy. Area: Diabetes.

phase 3 Insulin combination therapy Insulin receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Insulin Glargine - Insulin Aspart (Insulin Glargine - Insulin Aspart) — Hospital Universitario San Ignacio. This combination of long-acting basal insulin (glargine) and rapid-acting mealtime insulin (aspart) works together to regulate blood glucose by replacing the body's natural insulin secretion pattern.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Insulin Glargine - Insulin Aspart TARGET	Insulin Glargine - Insulin Aspart	Hospital Universitario San Ignacio	phase 3	Insulin combination therapy	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin combination therapy class)

Eli Lilly and Company · 3 drugs in this class
Hospital Universitario San Ignacio · 1 drug in this class
Peking University People's Hospital · 1 drug in this class
Riverside University Health System Medical Center · 1 drug in this class
Tehran University of Medical Sciences · 1 drug in this class
Université NAZI BONI · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Insulin Glargine - Insulin Aspart — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-glargine-insulin-aspart. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab